Skip to main content

Advertisement

SpringerLink
Log in

Loco-regional therapy and the risk of breast cancer-related lymphedema: a systematic review and meta-analysis

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

This meta-analysis was designed to assess the association between two loco-regional therapies, regional nodal irradiation (RNI) and axillary lymph node dissection (ALND), and breast cancer-related lymphoedema (BCRL).

Methods

We searched PubMed, Science Direct, Embase, and BMJ databases for clinical studies published between January 1, 2010 and January 1, 2020, which assessed risk factors and incidence/prevalence of BCRL. Two investigators independently selected articles to extract relative data and calculate corresponding exact binomial 95% confidence intervals (CIs). In total, 93 articles were reviewed, from which 19 studies were selected. The extracted data were pooled using a random-effects mixed model.

Results

The incidence of lymphedema in the selected studies ranged from 3% to 36.7%, with a pooled incidence of 14.29% (95% CI 13.79–14.79). The summary odds ratio/risk ratio (OR/RR) of ALND vs. no-ALND was 3.67 (95% CI 2.25–5.98) with a heterogeneity (I2) of 81% (P < 0.00001). After excluding the studies with an abnormally high risk of lymphedema from self-reporting, the summary hazard ratio (HR) was 2.99 (95% CI 2.44–3.66) with no heterogeneity (I2 = 0%, P = 0.83). The summary OR/RR of patients with vs. without radiotherapy (RT) was 1.82 (95% CI 0.92–3.59), but the RR of RT to breast/chest vs. both axillary and supraclavicular areas was 2.66 (95% CI 0.73–9.70).

Conclusion

Regional nodal irradiation has a significantly higher risk for developing lymphedema than irradiation of the breast/chest wall. Axillary dissection and axillary RT have a similar risk for early-onset of breast cancer-related lymphoedema, although the risk trends higher for axillary dissection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Vicini F, Shah C, Arthur D. The increasing role of lymphedema screening, diagnosis and management as part of evidence-based guidelines for breast cancer care. Breast J. 2016;22:358–9.

    Article  Google Scholar 

  2. Barroso-Sousa R, Paes FR, Vaz-Luis I, Batista RB, Costa RB, Losk K, et al. Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: a single institution retrospective study. Breast. 2016;30:136–40.

    Article  Google Scholar 

  3. Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102:111–8.

    Article  Google Scholar 

  4. Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg. 2016;264:413–20.

    Article  Google Scholar 

  5. Moreno AC, Shaitelman SF, Buchholz TA. A clinical perspective on regional nodal irradiation for breast cancer. Breast. 2017;34(Suppl 1):S85-s90.

    Article  Google Scholar 

  6. Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–10.

    Article  Google Scholar 

  7. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426–32 (discussion 32-3).

    Article  Google Scholar 

  8. Gillespie TC, Sayegh HE, Brunelle CL, Daniell KM, Taghian AG. Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surg. 2018;7:379–403.

    Article  Google Scholar 

  9. Ribeiro Pereira ACP, Koifman RJ, Bergmann A. Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up. Breast. 2017;36:67–73.

    Article  Google Scholar 

  10. Gross JP, Sachdev S, Helenowski IB, Lipps D, Hayes JP, Donnelly ED, et al. Radiation therapy field design and lymphedema risk after regional nodal irradiation for breast cancer. Int J Radiat Oncol Biol Phys. 2018;102:71–8.

    Article  Google Scholar 

  11. Rastogi K, Jain S, Bhatnagar AR, Gupta S, Bhaskar S, Spartacus RK. Breast cancer-related lymphedema in postmastectomy patients receiving adjuvant irradiation: a prospective study. Indian J Cancer. 2018;55:184–9.

    Article  Google Scholar 

  12. Shaitelman SF, Chiang YJ, Griffin KD, DeSnyder SM, Smith BD, Schaverien MV, et al. Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis. Breast Cancer Res Treat. 2017;162:201–15.

    Article  CAS  Google Scholar 

  13. Clough-Gorr KM, Ganz PA, Silliman RA. Older breast cancer survivors: factors associated with self-reported symptoms of persistent lymphedema over 7 years of follow-up. Breast J. 2010;16:147–55.

    Article  Google Scholar 

  14. Goldberg JI, Wiechmann LI, Riedel ER, Morrow M, Van Zee KJ. Morbidity of sentinel node biopsy in breast cancer: the relationship between the number of excised lymph nodes and lymphedema. Ann Surg Oncol. 2010;17:3278–86.

    Article  Google Scholar 

  15. Haddad P, Farzin M, Amouzegar-Hashemi F, Kalaghchi B, Babazadeh S, Mirzaei HR, et al. A multicentre cross-sectional study of arm lymphedema four or more years after breast cancer treatment in Iranian patients. Breast Cancer. 2010;17:281–5.

    Article  Google Scholar 

  16. Norman SA, Localio AR, Kallan MJ, Weber AL, Torpey HA, Potashnik SL, et al. Risk factors for lymphedema after breast cancer treatment. Cancer Epidemiol Biomarkers Prev. 2010;19:2734–46.

    Article  Google Scholar 

  17. Yang EJ, Park WB, Seo KS, Kim SW, Heo CY, Lim JY. Longitudinal change of treatment-related upper limb dysfunction and its impact on late dysfunction in breast cancer survivors: a prospective cohort study. J Surg Oncol. 2010;101:84–91.

    Article  Google Scholar 

  18. Wernicke AG, Goodman RL, Turner BC, Komarnicky LT, Curran WJ, Christos PJ, et al. A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance. Breast Cancer Res Treat. 2011;125:893–902.

    Article  Google Scholar 

  19. Asim M, Cham A, Banerjee S, Nancekivell R, Dutu G, McBride C, et al. Difficulties with defining lymphoedema after axillary dissection for breast cancer. N Z Med J. 2012;125:29–39.

    PubMed  Google Scholar 

  20. Crosby MA, Card A, Liu J, Lindstrom WA, Chang DW. Immediate breast reconstruction and lymphedema incidence. Plast Reconstr Surg. 2012;129:789e–95e.

    Article  Google Scholar 

  21. Ozcinar B, Guler SA, Kocaman N, Ozkan M, Gulluoglu BM, Ozmen V. Breast cancer related lymphedema in patients with different loco-regional treatments. Breast. 2012;21:361–5.

    Article  Google Scholar 

  22. Warren LE, Miller CL, Horick N, Skolny MN, Jammallo LS, Sadek BT, et al. The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study. Int J Radiat Oncol Biol Phys. 2014;88:565–71.

    Article  Google Scholar 

  23. Miller CL, Specht MC, Skolny MN, Horick N, Jammallo LS, O’Toole J, et al. Risk of lymphedema after mastectomy: potential benefit of applying ACOSOG Z0011 protocol to mastectomy patients. Breast Cancer Res Treat. 2014;144:71–7.

    Article  Google Scholar 

  24. Togawa K, Ma H, Sullivan-Halley J, Neuhouser ML, Imayama I, Baumgartner KB, et al. Risk factors for self-reported arm lymphedema among female breast cancer survivors: a prospective cohort study. Breast Cancer Res. 2014;16:414.

    Article  Google Scholar 

  25. Kilbreath SL, Refshauge KM, Beith JM, Ward LC, Ung OA, Dylke ES, et al. Risk factors for lymphoedema in women with breast cancer: a large prospective cohort. Breast. 2016;28:29–36.

    Article  CAS  Google Scholar 

  26. Nguyen TT, Hoskin TL, Habermann EB, Cheville AL, Boughey JC. Breast cancer-related lymphedema risk is related to multidisciplinary treatment and not surgery alone: results from a large cohort study. Ann Surg Oncol. 2017;24:2972–80.

    Article  Google Scholar 

  27. McDuff SGR, Mina AI, Brunelle CL, Salama L, Warren LEG, Abouegylah M, et al. Timing of lymphedema after treatment for breast cancer: when are patients most at risk? Int J Radiat Oncol Biol Phys. 2019;103:62–70.

    Article  Google Scholar 

  28. Tsai RJ, Dennis LK, Lynch CF, Snetselaar LG, Zamba GKD, Scott-Conner C. Lymphedema following breast cancer: the importance of surgical methods and obesity. Front Womens Health. 2018;3. https://doi.org/10.15761/FWH.1000144.

  29. Byun HK, Chang JS, Im SH, Kirova YM, Arsene-Henry A, Choi SH, Cho YU, Park HS, Kim JY, Suh CO, Keum KC, Sohn JH, Kim GM, Lee IJ, Kim JW, Kim YB. Risk of lymphedema following contemporary treatment for breast cancer: an analysis of 7617 consecutive patients from a multidisciplinary perspective. Ann Surg. 2019. https://doi.org/10.1097/SLA.0000000000003491.

    Article  Google Scholar 

  30. Invernizzi M, Michelotti A, Noale M. Breast cancer systemic treatments and upper limb lymphedema: a risk-assessment platform encompassing tumor-specific pathological features reveals the potential role of trastuzumab. J Clin Med. 2019;8. https://doi.org/10.15761/FWH.1000144.

  31. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98:599–609.

    Article  Google Scholar 

  32. Smith MJ, Gill PG, Wetzig N, Sourjina T, Gebski V, Ung O, et al. Comparing patients’ and clinicians’ assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). Breast Cancer Res Treat. 2009;117:99–109.

    Article  Google Scholar 

  33. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–53.

    Article  Google Scholar 

Download references

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Author notes

  1. Yan Lin and Ying Xu contributed equally to this work.

Authors and Affiliations

  1. Department of Breast Disease, Peking Union Medical College Hospital, Peking Union Medical College, 1 Shuaifuyuan, Wangfujing, Beijing, 100730, China

    Yan Lin, Ying Xu, Changjun Wang, Yu Song, Xin Huang, Xiaohui Zhang, Xi Cao & Qiang Sun

Authors
  1. Yan Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ying Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Changjun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xin Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaohui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xi Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Qiang Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qiang Sun.

Ethics declarations

Conflict of interest

We have no conflict of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 626 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, Y., Xu, Y., Wang, C. et al. Loco-regional therapy and the risk of breast cancer-related lymphedema: a systematic review and meta-analysis. Breast Cancer 28, 1261–1272 (2021). https://doi.org/10.1007/s12282-021-01263-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-021-01263-8

Keywords

Search

Navigation